Vivostat® is pleased to participate for the first time in The Meniscus 2027. As one of the leading international meetings dedicated to meniscus preservation, regeneration, and joint health, the congress brings together orthopaedic surgeons, sports medicine specialists and researchers committed to advancing patient outcomes. We look forward to engaging with the meniscus and sports medicine community and sharing innovative regenerative solutions.

Vivostat® is the world’s only on-site solution for preparing and applying autologous platelet-enriched fibrin matrices directly from the patient’s own blood. For more than two decades, Vivostat® technology has supported clinicians across multiple surgical specialties by providing personalized regenerative and haemostatic solutions.

At The Meniscus 2027, we are excited to present ArthroZheal®, our dedicated regenerative solution designed to support biological healing and tissue regeneration in orthopaedic and sports medicine applications. By combining the regenerative potential of autologous platelet-rich fibrin, ArthroZheal® offers clinicians a unique approach to enhancing the body’s natural healing processes.

As the focus in orthopaedics increasingly shifts toward tissue preservation and regenerative treatment strategies, biological solutions are becoming an important part of clinical practice. Through its autologous regenerative matrix, ArthroZheal® is designed to support tissue repair while avoiding the use of exogenous additives or donor-derived materials.

Visit our booth to learn more about the Vivostat® and ArthroZheal®, and discover how autologous regenerative technologies can support the future of meniscus preservation, cartilage repair and orthopaedic tissue regeneration.